The role of advanced glycosylation end-products in the pathogenesis of atherosclerosis

Nephrology Dialysis Transplantation

Volumn 11, Issue SUPPL. 5, 1996, Pages 31-33

  Makita, Zenji ^a   Yanagisawa, Katsuyuki ^a   Kuwajima, Satoru ^a   Bucala, Richard ^b   Vlassara, Helen ^b   Koike, Takao ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b PICOWER INST FOR MEDICAL RESEARCH   (United States)

Author keywords

Advanced glycosylation end products; Atherosclerosis; Diabetes mellitus; Low density lipoproteins

Indexed keywords

APOLIPOPROTEIN B; APOPROTEIN; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID;

ATHEROSCLEROSIS; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; KIDNEY FAILURE; LIPID OXIDATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN GLYCOSYLATION;

EID: 0030512623     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/11.supp5.31     Document Type: Conference Paper

References (14)

1. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation endproducts in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-1321
2. Monnier VM, Vishwanath N, Frank KE, Elmets CE, Dauchot P, Kohn RR. Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N Engl J Med 1986; 314: 403-408
3. Bucala R, Makita Z, Koschinsky T et al. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 1993; 90: 6434-6438
4. Bucala R, Makita Z, Vega G et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 1994; 91: 9441-9445
5. Radoff S, Makita Z, Vlassara H. Radio receptor assay for advanced glycosylation end products. Diabetes 1991; 40: 1731-1738
6. Makita Z, Radoff S, Rayfield E et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325: 836-842
7. Makita Z, Vlassara H, Cerami A, Bucala R. Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 1992; 267: 5133-5138
8. Makita Z, Bucala R, Rayfield EJ et al. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 1994; 343: 1519-1522
9. Papanastasiou P, Grass L, Rodela H, Patrikarea A, Oreopoulos D, Diamandis EP. Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney Int 1994; 46: 216-222
10. Dolhofer-Bliesener, Lechner B, Deppisch R, Ritz E, Gerbitz. Immunological determination of advanced glycosylation end-products in human blood and urine. Nephrol Dial Transplant 1995; 10: 657-664
11. Bucala R, Mitchell R, Arnold K, Innerarity T, Vlassara H, Cerami A. Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor. J Biol Chem 1995; 270: 10828-10832
12. Zyzak D, Richardson JM, Thorpe SR, Baynes JW. Formation of reactive intermediates from Amadori compounds under physiological conditions. Arch Biochem Biophys 1995; 316: 547-554
13. Steinberg D, Parthasarathy S, Carew T, Khoo JC, Witztum JL. Beyond cholesterol modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-924
14. Nakamura N, Horii N, Nishino T, Shiiki H, Sakaguchi N, Kogoshima T, Dohi K, Makita Z, Vlassara H, Bucala R. Immunohistochemical localization of advanced glycosylation endproducts in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 1993; 143: 1649-1656